The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex

By John R. Prensner, Matthew K. Iyer, Anirban Sahu, I. Asangani, Q. Cao, Lalit R. Patel, I. Vergara, E. Davicioni, N. Erho, M. Ghadessi and 19 more. Nature Genetics, 2013

677 citations recorded by the source corpus.

Prostate cancers remain indolent in the majority of individuals but behave aggressively in a minority. The molecular basis for this clinical heterogeneity remains incompletely understood. Here we characterize a long noncoding RNA termed SChLAP1 (second chromosome locus associated with prostate-1; also called LINC00913) that is overexpressed in a subset of prostate cancers. SChLAP1 levels independently predict poor outcomes, including metastasis and prostate cancer–specific mortality. In vitro and in vivo gain-of-function and loss-of-function experiments indicate that SChLAP1 is critical for cancer cell invasiveness and metastasis. Mechanistically, SChLAP1 antagonizes the genome-wide localization and regulatory functions of the SWI/SNF chromatin-modifying complex. These results suggest that SChLAP1 contributes to the development of lethal cancer at least in part by antagonizing the tumor-suppressive functions of the SWI/SNF complex.

Subfields: Cancer Research, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/005b0e31c7c2435ffeb7d76c04299e67c8317f1c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Alan Ashworth
2. Arul M. Chinnaiyan
3. B. Bruneau
4. R. DePinho
5. Kyle Kai-How Farh
6. David P. Bartel

In Immunology

1. Di Zhao
2. D. Spring
3. E. Small
4. Guocan Wang
5. R. DePinho

In Molecular Biology

1. Alan Ashworth
2. Arul M. Chinnaiyan
3. Serafim Batzoglou
4. B. Bruneau
5. Swetansu K. Hota
6. Travis J. Barnard
7. R. DePinho
8. Kyle Kai-How Farh

Citations in the corpus

• Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19 (2018, background): “LncRNAs are aberrantly expressed in multiple human cancers, such as colorectal, prostate, breast, liver, brain cancer, renal, and bladder cancer, where they may modulate numerous hallmarks to promote or inhibit CRC development, invasion, and metastasis including proliferation, apoptosis, metastasis ”
• Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers (2015, background): “In recent years, increasing evidence has suggested that a novel class of non-coding RNA, long non-coding RNA (lncRNA), is commonly altered at various stages of cancer progression (3,4).”
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. (2018, positive): “We also identified novel fusions between coding and non-coding genes, exemplified by SCHLAP1, a lncRNA highly enriched in a subset of aggressive prostate cancers (Prensner et al., 2013).”
• Genetics and biology of prostate cancer (2018, background): “In addition, the function of the SWI/SNF complex was antagonized by the long noncoding RNA SChLAP1, which contributes to the oncogenic function of SChLAP1 (Prensner et al. 2013).”
• ATP-dependent chromatin remodeling during mammalian development (2016, background): “These studies showed that, during early somite differentiation, the muscle-specific miRNAs miR-133 and miR1/206 repress the translation of BAF60A and BAF60B, resulting in a switch from primarily a BAF60A-containing complex to a BAF60C-containing complex.”
• MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA–DNA triplex structures (2015, neutral): “[0-15] MEG3”